Project Grant R21CA280566
Award Date
7/1/24
Completion Date
6/30/26
Dollars Obligated
$415K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.396 Cancer Biology Research), supports research to increase the efficacy of non-activated chimeric antigen receptor (CAR) T cells for cancer treatment. The $587,108 award aims to enhance the transduction efficiency and therapeutic potency of non-activated CAR T cells by modulating the type I interferon (IFN1) signaling pathway. Key objectives include: Investigating the impact of IFN1 blockade on CAR lentivirus...
This federal Project Grant award, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), aims to conduct comprehensive molecular and clinical characterization of acute and chronic neurotoxicity following chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies. The $1,220,394 award to the Sloan-Kettering Institute for Cancer Research, spanning from September 2024 to August 2029, will investigate the pathogenesis of acute immune...
This federal Project Grant award of $1,313,806.00 from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), supports research conducted by the Sloan-Kettering Institute for Cancer Research in New York, NY. The key focus is on developing and translating chimeric antigen receptor (CAR) T-cell therapies targeting the cancer-associated antigen mesothelin for the treatment of solid tumors, particularly malignant pleural mesothelioma. The research aims to...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) to the Trustees of Dartmouth College supports research to deconvolute the heterogeneity of chimeric antigen receptor (CAR) T cells and engineer durable antitumor immunity. The $604,627 award, effective January 1, 2025 through December 31, 2029, will test the hypothesis that CAR T-cell heterogeneity can be deconvolved to understand how individual T-cell subsets behave in vivo and use these...
The federal Project Grant award of $1,602,000 from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) will fund research to develop and optimize a new class of Epigenetic Reprogramming Factors (ERFs) to enhance Chimeric Antigen Receptor (CAR) T cell fitness and antitumor function. The award, which will span 3 years from September 2024 to August 2027, will be executed by The Children's Hospital of Philadelphia (CHOP) Research Institute. The goal is to...
The National Cancer Institute awarded a $195,766 Project Grant (CFDA 93.395 Cancer Treatment Research) to Yale University for the project "Synthetic Mechano-Transduction for Improved Cell Therapies in Immuno-Oncology". The project aims to develop a mechano-transduction platform to enhance chimeric antigen receptor (CAR) T-cell therapies for treating solid tumors. Key objectives include: Measuring forces along key immune receptors using force sensors developed by the researchers....
The National Cancer Institute (NCI) awarded a 5-year, $432,837.14 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to Stanford University. The funding will support research to define the key CAR T cell subsets that mediate efficacy in large B-cell lymphoma (LBCL) patients and overcome an immune suppression mechanism that limits CAR T cell therapy. The project aims to use single-cell sequencing and methylation analyses to pinpoint optimal CAR T cell clones and uncover the...
This federal Project Grant award for $1,108,391.72 was provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Leland Stanford Junior University to conduct research focused on improving chimeric antigen receptor (CAR) T cell therapies for large B-cell lymphoma (LBCL). The key research goals are: 1) to define the most therapeutically relevant CAR T cell subsets in LBCL patients, and 2) to overcome an immune suppression mechanism of resistance to CAR T cell...
The Project Grant award titled "Dissecting the Mechanism for Transient ER Stress-Induced Anti-Tumor T Cell Response" is funded by the National Cancer Institute (NCI) under the Cancer Biology Research (CFDA 93.396) federal grant program. The $626,534 award will support research at the Medical University of South Carolina (MUSC) to investigate how inducing transient endoplasmic reticulum (ER) stress can improve the anti-tumor function of T cells. The key objectives are to: Determine...
This Project Grant award of $893,184 from the National Cancer Institute's Cancer Research Manpower Program (CFDA 93.398) supports research to develop chimeric antigen receptor (CAR) T-cell therapies for renal cell carcinoma. The primary objectives are to: 1) Determine the effect of locally secreted VEGF blockade on CD70 CAR-T cell biology, function, and exhaustion; and 2) Evaluate the ability of CD70 CAR-T cells with VEGF blockade to modulate tumor proliferation, angiogenesis, and endothelial...